Form 8-K · Current report
ResMed| 8-K, filed Aug 6, 2026
- Filed
- CIK
- 0000943819
- Accession no.
- 0001193125-26-337962
Summary
ResMed reported fourth-quarter revenue up 9% to a record $1.5 billion and fiscal year 2026 revenue up 10% to $5.7 billion, and its board declared a quarterly dividend of $0.66 per share, a 10% increase. The company also said it agreed to sell its MatrixCare business, completed the acquisition of Noctrix Health, and guided to returning more than $1.85 billion to shareholders in fiscal 2027.
Key points
- Q4 GAAP diluted earnings per share rose 2% to $2.64, while non-GAAP diluted earnings per share rose 16% to $2.95.
- Full-year fiscal 2026 GAAP diluted earnings per share were $10.43 and non-GAAP diluted earnings per share were $11.17, up 17%.
- The MatrixCare sale is expected to close in the first quarter of ResMed's fiscal year 2027.
- ResMed returned $1.0 billion to shareholders through share repurchases and dividends during fiscal 2026, and reported $1.6 billion in free cash flow for the year.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. On August 6, 2026, we issued the press release furnished as Exhibit 99.1. The press release describes the results of our operations for the quarter and fiscal year ended June 30, 2026. The information furnished in this Current Report on Form 8-K under Item 2.02 and the attached exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 8.01. Other Events. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.